©The Author(s) 2025.
World J Gastroenterol. Dec 14, 2025; 31(46): 111631
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.111631
Published online Dec 14, 2025. doi: 10.3748/wjg.v31.i46.111631
Figure 4 IGF2BP3 regulates the growth of gastric cancer in vivo.
A: Nude mouse tumor-bearing model; B: Tumor growth curve; C and D: Images (C) and weights (D) of xenografted tumors; E: Representative images of tumor tissue sections stained with hematoxylin and eosin, scale bar: 20 μm; F: Representative image of Ki67 immunohistochemical staining in tumor tissue sections. Scale bar: 100 μm. Data are shown as the mean ± SD. bP < 0.01. dP < 0.0001. shNC: Short hairpin RNA-negative control; shIGF2BP3: Short hairpin RNA-IGF2BP3; HE: Hematoxylin and eosin.
- Citation: Si Y, Tian B, Zhang R, Xuan MD, Liu KY, Jiao J, Han SS, Li HF, Hu YH, Zhao HY, He WJ, Wang J, Liu T, Yu WF. IGF2BP3 binds to FBXO32 to activate the cyclic guanosine monophosphate-protein kinase G pathway, promoting gastric cancer progression. World J Gastroenterol 2025; 31(46): 111631
- URL: https://www.wjgnet.com/1007-9327/full/v31/i46/111631.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i46.111631